Pharmacy Faculty Publications

An Open-Label Pilot Study of Transdermal Selegiline for Depression in Parkinson's Disease Patients

Document Type

Abstract

Publication Date

5-15-2008

Journal Title

Movement Disorders

Volume

23

Issue

S1

First Page

S304

Last Page

S305

DOI

10.1002/mds.22133

Abstract

Depression is one of the most common non-motor symptoms of PD with reported prevalence rates from 40 to 80%. Transdermal selegiline was recently approved for the treatment of depression. There have been no reports of transdermal selegiline for depression in PD patients; however, other forms of selegiline have been shown to be effective treatments for controlling PD symptoms. The goal of this study was to determine if transdermal selegiline can reduce depression without worsening and potentially improving the symptoms of PD.

Keywords

Parkinson's Disease, depression

Comments

Abstract 931

Link to Full Text

Share

COinS